Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS.

The objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion.

The study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Central Nervous System Diseases Cranial Nerve Diseases Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Eye Diseases Immune System Diseases Internuclear Ophthalmoplegia Nervous System Diseases Ocular Motility Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Les Hôpitaux Universitaires

Strasbourg, 67 200, France

Location contact

Kévin BIGAUT

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with internuclear ophthalmoplegia listed as a primary or associated diagnosis
Patients hospitalized in a neurology department

Exclusion criteria

Patients under 18 years of age

Treatment and study plan

Primary outcomes

Analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis.

Time frame: 1 year

Proportion of patients with isolated internuclear ophthalmoplegia who converted to multiple sclerosis during follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

Kévin BIGAUT

CONTACT

[email protected]

+33 3 88 12 60 96

Sebille COLIN

CONTACT

[email protected]

+33 3 88 11 52 17

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: INO&MS

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2027
First posted: May 1, 2026
Registry last updated: May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting